Karyopharm Therapeutics (KPTI) Share-based Compensation (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Share-based Compensation came in at $2.8 million in Q3 2025, down 32.97% YoY from $4.2 million in Q3 2024, and down 21.26% on a QoQ basis from $3.6 million in Q2 2025.
Karyopharm Therapeutics (KPTI) Share-based Compensation (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Share-based Compensation data on file, last reported at $2.8 million in Q3 2025.
- Quarterly Share-based Compensation fell 32.97% year-over-year to $2.8 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $10.1 million (down 46.22% YoY) and the FY2025 annual result came in at $8.7 million, down 52.78% from the prior year.
- Share-based Compensation slipped to $2.8 million in Q3 2025, from $3.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $15.1 million in Q2 2022 to a low of $2.8 million in Q3 2025.
- A 5-year average of $6.1 million and a median of $5.4 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation surged 85.53% — and 2023, when it tumbled 59.85%.
- Tracing KPTI's Share-based Compensation over 5 years: stood at $6.9 million in 2021, then fell by 10.13% to $6.2 million in 2022, then fell by 16.05% to $5.2 million in 2023, then retreated by 25.43% to $3.9 million in 2024, then decreased by 27.46% to $2.8 million in 2025.
- The last three Share-based Compensation figures came in at $2.8 million (Q3 2025), $3.6 million (Q2 2025), and $3.8 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | 1.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.93 Mn |
| Jun 30, 2026 | 1.93 Mn |
| Dec 31, 2025 | 3.90 Mn |
| Dec 31, 2025 | 3.90 Mn |
| Sep 30, 2025 | 2.80 Mn |
| Sep 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 3.56 Mn |
| Jun 30, 2025 | 3.56 Mn |
| Mar 31, 2025 | 3.78 Mn |
| Mar 31, 2025 | 3.78 Mn |
| Dec 31, 2024 | 3.86 Mn |
| Dec 31, 2024 | 3.86 Mn |
| Sep 30, 2024 | 4.18 Mn |
| Sep 30, 2024 | 4.18 Mn |
| Jun 30, 2024 | 5.41 Mn |
| Jun 30, 2024 | 5.41 Mn |
| Mar 31, 2024 | 5.41 Mn |
| Mar 31, 2024 | 5.41 Mn |
| Dec 31, 2023 | 5.18 Mn |
| Dec 31, 2023 | 5.18 Mn |